You are here:

elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate) (Stribild)

Advice

In the absence of a submission from the holder of the marketing authorisation

elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (as fumarate) (Stribild®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of HIV‑1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV‑1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate) (Stribild)
SMC Drug ID: 1310/18
Manufacturer: Gilead Sciences Ltd
Indication: Treatment of HIV‑1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV‑1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 February 2018

Back